Are higher prices of anticancer medicines reflected in better outcomes for Patients?
One presentation by Villafuerte et al. (1587MO) and two by Vokinger et al. (1593P and 1586MO) investigated whether there is a correlation between the cost of new drugs for cancer treatment and their benefit. The analysis included all FDA and EMA approved drugs in the period 2005 to 2018 for the treatment of solid cancers. It was concluded that no relation exists between the drug price and benefit to society and patients.
In other words, new expensive drugs do not necessary filter into improved patient outcome and a positive health economic benefit.